Skip to main content

Table 2 Antimicrobial activity of antimicrobial agents against members of the Enterobacteriaceae collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

 

MIC 90 (mg/L)

MIC range mg/L

% susceptible

% resistant

Enterobacter spp. (n = 32,987)

    

AMK

4

≤0.5– ≥ 128

97.2

1.8

FEP

8

≤0.5– ≥ 64

91.7

5.8

CRO

64

≤0.06– ≥ 128

61.7

35.1

IPM (n = 6,963)

1

≤0.06– ≥ 32

95.7

1.1

LVX

8

≤0.008– ≥ 16

86.8

10.7

MEM (n = 26,024)

0.25

≤0.06– ≥ 32

97.2

1.9

MIN

16

≤0.5– ≥ 32

73.7

12.5

TZP

128

≤0.06– ≥ 256

76.1

12.1

TGC

2

≤0.008– ≥ 32

95.4

1.1

Enterobacter spp., Car-R (n = 578)

   

AMK

≥128

≤0.5– ≥ 128

68.3

23.7

FEP

≥64

≤0.5– ≥ 64

35.6

52.2

CRO

≥128

≤0.06– ≥ 128

6.7

91.9

LVX

≥16

≤0.008– ≥ 16

39.1

54.0

MIN

≥32

≤0.5– ≥ 32

39.8

38.8

TZP

≥256

≤0.06– ≥ 256

22.5

60.7

TGC

4

0.06–16

83.0

5.2

Escherichia coli (n = 37,038)

  

AMK

8

≤0.5– ≥ 128

98.3

0.9

AMC

32

≤0.12– ≥ 64

66.6

14.2

AMP

≥64

≤0.5– ≥ 64

35.6

63.5

FEP

16

≤0.5– ≥ 64

88.5

9.0

CRO

64

≤0.06– ≥ 128

79.1

19.9

IPM (n = 8,091)

0.5

≤0.06– ≥ 32

99.4

0.3

LVX

≥16

≤0.008– ≥ 16

66.1

31.5

MEM (n = 28,947)

≤0.06

≤0.06– ≥ 32

99.1

0.5

MIN

16

≤0.5– ≥ 32

77.0

13.0

TZP

16

≤0.06– ≥ 256

91.3

4.4

TGC

0.5

≤0.008– ≥ 32

>99.9

<0.1

Escherichia coli, ESBL-positive (n = 5,178)

  

AMK

16

≤0.5– ≥ 128

94.2

2.7

AMC

32

0.25– ≥ 64

31.3

28.5

AMP

≥64

1– ≥ 64

0.4

99.5

FEP

≥64

≤0.5– ≥ 64

32.4

54.8

CRO

≥128

≤0.06– ≥ 128

1.3

97.5

IPM (n = 643)

0.5

≤0.06–8

98.1

0.6

LVX

≥16

≤0.008– ≥ 16

18.1

78.5

MEM (n = 4,535)

0.12

≤0.06– ≥ 32

98.5

0.8

MIN

≥32

≤0.5– ≥ 32

63.2

22.7

TZP

64

≤0.06– ≥ 256

77.0

9.9

TGC

0.5

≤0.008–8

>99.9

<0.1

Escherichia coli, Car-R (n = 181)

   

AMK

≥128

≤0.5– ≥ 128

50.8

38.1

AMC

≥64

2– ≥ 64

11.6

76.8

AMP

≥64

1– ≥ 64

8.3

90.6

FEP

≥64

≤0.5– ≥ 64

28.2

56.4

CRO

≥128

≤0.06– ≥ 128

9.9

90.1

LVX

≥16

≤0.008– ≥ 16

22.7

71.3

MIN

≥32

≤0.5– ≥ 32

43.1

35.4

TZP

≥256

1– ≥ 256

29.3

55.8

TGC

2

≤0.008–16

97.2

1.7

Klebsiella oxytoca (n = 6,940)

  

AMK

4

≤0.5– ≥ 128

98.8

0.8

AMC

32

0.25– ≥ 64

79.4

12.4

FEP

2

≤0.5– ≥ 64

96.1

2.4

CRO

16

≤0.06– ≥ 128

81.5

16.2

IPM (n = 1,454)

0.5

≤0.06– ≥ 32

99.2

0.5

LVX

2

≤0.008– ≥ 16

92.1

5.7

MEM (n = 5,486)

0.12

≤0.06– ≥ 32

98.8

0.8

MIN

8

≤0.5– ≥ 32

88.2

5.6

TZP

≥256

≤0.06– ≥ 256

85.1

12.5

TGC

1

≤0.008–16

98.7

0.2

Klebsiella pneumoniae (n = 28,928)

  

AMK

16

≤0.5– ≥ 128

94.4

3.1

AMC

32

≤0.12– ≥ 64

67.9

20.2

FEP

≥64

≤0.5– ≥ 64

81.0

15.8

CRO

≥128

≤0.06– ≥ 128

70.1

28.8

IPM (n = 6,008)

0.5

≤0.06– ≥ 32

97.7

1.6

LVX

≥16

≤0.008– ≥ 16

77.4

19.5

MEM (n = 22,920)

0.25

≤0.06– ≥ 32

93.5

5.4

MIN

16

≤0.5– ≥ 32

71.4

18.0

TZP

≥256

≤0.06– ≥ 256

79.4

14.9

TGC

2

≤0.008– ≥ 32

95.3

0.8

Klebsiella pneumoniae, ESBL-positive (n = 5,899)

  

AMK

32

≤0.5– ≥ 128

83.6

9.5

AMC

≥64

≤0.12– ≥ 64

18.3

48.3

FEP

≥64

≤0.5– ≥ 64

31.9

56.6

CRO

≥128

≤0.06– ≥ 128

1.4

97.0

IPM (n = 946)

1

≤0.06– ≥ 32

91.3

6.1

LVX

≥16

≤0.008– ≥ 16

35.2

57.1

MEM (n = 4,953)

2

≤0.06– ≥ 32

88.3

9.0

MIN

≥32

≤0.5– ≥ 32

48.4

34.5

TZP

≥256

≤0.06– ≥ 256

44.3

39.2

TGC

2

≤0.008– ≥ 32

92.3

1.6

Klebsiella pneumoniae, Car-R (n = 1,330)

   

AMK

≥128

≤0.5– ≥ 128

57.5

18.4

AMC

≥64

1– ≥ 64

1.7

96.5

FEP

≥64

≤0.5– ≥ 64

7.4

85.0

CRO

≥128

≤0.06– ≥ 128

1.8

97.5

LVX

≥16

≤0.008– ≥ 16

10.1

85.9

MIN

≥32

≤0.5– ≥ 32

52.2

25.3

TZP

≥256

0.12– ≥ 256

4.7

91.3

TGC

2

0.03–16

92.0

2.1

Klebsiella pneumoniae, ESBL-positive, Car-R (n = 505)

  

AMK

≥128

≤0.5– ≥ 128

59.8

15.6

AMC

≥64

8– ≥ 64

0.8

96.2

FEP

≥64

1– ≥ 64

4.8

83.6

CRO

≥128

2– ≥ 128

0.0

99.6

LVX

≥16

0.015– ≥ 16

6.7

88.5

MIN

≥32

≤0.5– ≥ 32

49.7

28.5

TZP

≥256

1– ≥ 256

2.0

92.9

TGC

2

0.12–16

91.1

3.6

Serratia marcescens (n = 13,006)

  

AMK

8

≤0.5– ≥ 128

96.5

2.1

AMC

≥64

≤0.12– ≥ 64

3.3

93.9

AMP (n = 12,963)

≥64

≤0.5– ≥ 64

2.7

88.0

FEP

2

≤0.5– ≥ 64

95.2

3.5

CRO

16

≤0.06– ≥ 128

79.6

16.9

IPM (n = 2,865)

1

≤0.06–8

92.2

1.2

LVX

2

≤0.008– ≥ 16

92.9

4.4

MEM (n = 10,141)

0.25

≤0.06– ≥ 32

97.4

1.9

MIN

8

≤0.5– ≥ 32

72.3

8.5

TZP

16

≤0.06– ≥ 256

92.4

3.2

TGC

2

≤0.008– ≥ 32

95.8

0.7

Serratia marcescens, Car-R (n = 229)

   

AMK

≥128

≤0.5– ≥ 128

67.7

24.9

AMC

≥64

≤0.12– ≥ 64

0.4

99.1

AMP

≥64

16– ≥ 64

0.0

95.2

FEP

≥64

≤0.5– ≥ 64

51.1

39.3

CRO

≥128

≤0.06– ≥ 128

26.2

70.3

LVX

≥16

0.03– ≥ 16

60.7

31.0

MIN

16

≤0.5– ≥ 32

54.6

26.6

TZP

≥256

0.25– ≥ 256

45.4

41.0

TGC

4

0.12–16

83.8

4.8

  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ESBL, extended-spectrum β-lactamase; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.